New Ray Medicine International Holding Limited (HKG:6108)
Hong Kong · Delayed Price · Currency is HKD 0.2160
-0.0010 (-0.46%)
Sep 11, 2026, 2:16 PM HKT
HKG:6108 Income Statement
Financials in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 199.09 | 130.37 | 93.95 | 50.15 | 89.77 | 335.38 | |
Revenue Growth | 63.29% | 38.78% | 87.31% | -44.13% | -73.23% | 151.76% |
Cost of Revenue | 176.74 | 114.23 | 95.57 | 38.81 | 118.96 | 306.89 |
Gross Profit | 22.36 | 16.15 | -1.62 | 11.34 | -29.18 | 28.49 |
Selling, General & Admin | 26.76 | 24.57 | 30.6 | 28.7 | 39.61 | 30.92 |
Operating Expenses | 35.36 | 32.45 | 36.31 | 32.76 | 44.23 | 35.57 |
Operating Income | -13 | -16.3 | -37.94 | -21.42 | -73.42 | -7.08 |
Interest Expense | -0.13 | -0.14 | -0.1 | -0.03 | -0.18 | -0.28 |
Interest & Investment Income | 0.48 | 0.69 | 2.53 | 3.68 | 3.37 | 1.3 |
Earnings From Equity Investments | - | - | - | - | - | 1.11 |
Currency Exchange Gain (Loss) | -0.75 | -0.13 | -0.67 | -0.57 | -10.63 | 4.25 |
Other Non Operating Income (Expenses) | 0.01 | 0.01 | 0.05 | -2.11 | 0.07 | 0.09 |
EBT Excluding Unusual Items | -13.4 | -15.88 | -36.13 | -20.45 | -80.79 | -0.62 |
Gain (Loss) on Sale of Investments | -2.76 | -4.18 | 3.93 | 0.42 | - | -2.99 |
Gain (Loss) on Sale of Assets | 0.11 | 0.12 | 0.14 | 0.48 | 0.38 | -0.01 |
Asset Writedown | - | - | - | -2.8 | - | - |
Other Unusual Items | - | - | - | - | 0.12 | - |
Pretax Income | -16.05 | -19.94 | -32.06 | -22.34 | -80.29 | -3.61 |
Income Tax Expense | 0.13 | 0.13 | -1.05 | -0.17 | -2.34 | -0.78 |
Net Income | -16.18 | -20.07 | -31.01 | -22.17 | -77.95 | -2.82 |
Net Income to Common | -16.18 | -20.07 | -31.01 | -22.17 | -77.95 | -2.82 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 185 | 168 | 167 | 167 | 167 | 167 |
Shares Outstanding (Diluted) | 185 | 168 | 167 | 167 | 167 | 167 |
Shares Change | 10.49% | 0.49% | - | - | - | - |
EPS (Basic) | -0.09 | -0.12 | -0.19 | -0.13 | -0.47 | -0.02 |
EPS (Diluted) | -0.09 | -0.12 | -0.19 | -0.13 | -0.47 | -0.02 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | - | -54.45 | -5.39 | -45.45 | -9.02 | -58.45 |
Free Cash Flow Per Share | - | -0.32 | -0.03 | -0.27 | -0.05 | -0.35 |
Gross Margin | 11.23% | 12.39% | -1.73% | 22.61% | -32.51% | 8.49% |
Operating Margin | -6.53% | -12.50% | -40.38% | -42.71% | -81.78% | -2.11% |
Profit Margin | -8.13% | -15.39% | -33.01% | -44.20% | -86.83% | -0.84% |
Free Cash Flow Margin | - | -41.77% | -5.73% | -90.62% | -10.04% | -17.43% |
EBITDA | -11.67 | -14.54 | -36.23 | -16.63 | -68.46 | -2.86 |
EBITDA Margin | -5.86% | -11.15% | -38.57% | -33.15% | -76.27% | -0.85% |
D&A For EBITDA | 1.33 | 1.76 | 1.7 | 4.8 | 4.95 | 4.22 |
EBIT | -13 | -16.3 | -37.94 | -21.42 | -73.42 | -7.08 |
EBIT Margin | -6.53% | -12.50% | -40.38% | -42.71% | -81.78% | -2.11% |